Thrombotargets' scientific team comprises highly qualified professionals, whose international education and experience provides them with expertise in the development of products in the cardiovascular and hemostasis areas, and a broad experience in Molecular Biology, Pharmacology and Clinical Development.
MBA. Entrepreneur and Founder of over 10 companies in different sectors. Member of the Board of Directors of Biotech Angels. President & Founder of Bejar Signature, Founder of Eurofragance.
Product Development Director
He started his research carreer at Cardiology lab, University Hospital Marqués de Valdecilla, later on at the Department of Medicine and Surgery, Univ. of Cantabria. Then Department of Pharmacology, University of Alberta, Canada. Researcher at Laboratorios Lacer, where he became the Head of Animal Assays Unit. Started as Pharmacology Head at Thrombotargets Europe in 2005.
Comm. Operations Director
Biologist. She started her career at Laboratorios del Dr. Esteve, then Boehringer Ingelheim. She founded and managed Clinical Reference, where she was also Technical Director and BD Manager. She joined Thrombotargets in 2011.
Chemical Engineer, BSc / MSc Advanced Biotechnology (IQS, MIT). Teaching Assistant at MIT, then Predoctoral researchear at IQS. Later on Bioprocess Engineer first at Neuron Bio, then at Neol Biosolutions. He joined Thrombotargets in 2015.
Acting head of Quality Assurance
PhD in Biology. He did his PhD at the College of Medicine in New Jersey. Then, Head of Fermentation Department at the Venezuelan Institute of Scientific Research. Later on Director of Fermentation Development, at Xoma Corp., Berkeley. Later on Scientific Director at Berlex Biosciences. Now he is consultant in Bio processes at BPTC, and QA of Thrombotargets since 2010.
MD, BSc Biology, PhD Biology. He started his research career as Tenured Researcher at Fundació Clinic, then at the Institute for Biomedical Research in Barcelona (IIBB-CSIC). Head of Preclinical Research at Institute of High Technology (IAT-CRC). He joined Thrombotargets in 2012.